

BF BIOSCIENCES LIMITED

A SUBSIDIARY OF FEROZSONS LABORATORIES LIMITED

Ref: COR/2024/11-2(C) Date: January 14, 2024

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

MATERIAL INFORMATION

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

We are writing in response to investor queries on a misleading news being circulating on social media regarding our product Eterna specifically the comparative prices being mentioned in the news. Eterna is not a new launch, the product is in market since May 2023 and the competition prices mentioned in the news are not correct.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yourstruly,

Abdur Rehman
Company Secretary

CC: Director Enforcement- Securities and Exchange Commission of Pakistan.

Rawalpindi

Karachi Sales Office:

News Being circulating on Media

BF Biosciences Just Changed the Game – ETERNA is Here!

BF Biosciences has just redefined the future with Eterna—a biosimilar breakthrough for autoimmune diseases like rheumatoid arthritis, psoriasis, and more—delivering world-class treatment at an unheard-of price.

₩ Why This Changes Everything:
Same power as Pfizer's Enbrel (PKR 618,550), Amgen's Benepali (PKR 457,588), & Novartis' Erelzi (PKR 385,308)—but just PKR 12,000/month
Affordable, Accessible, Unstoppable—finally, cutting-edge treatment for everyone
☑ Locally Produced, USFDA-Standard—the biggest biotech breakthrough in Pakistan

This isn't just innovation—it's a revolution in healthcare. The future belongs to those who disrupt, and BF Biosciences is leading the charge.